<DOC>
	<DOCNO>NCT03014648</DOCNO>
	<brief_summary>This phase II clinical trial aim evaluate efficacy PD-L1 inhibition atezolizumab advance squamous non-squamous NSCLC patient previously treat anti-PD-1 therapy either nivolumab pembrolizumab . In order account variability response kinetics PD-1 direct therapy , patient enrol 3 parallel cohort base best overall response PD-1 direct therapy . - Cohort 1 ( progressive disease ) - Cohort 2 ( stable disease minimum 12 week therapy ) - Cohort 3 ( partial complete response follow progressive disease )</brief_summary>
	<brief_title>Evaluating Efficacy Atezolizumab Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Atezolizumab give day 1 21-day cycle 1200 mg IV . Radiographic assessment disease response occur every 6 week treatment . Confirmatory scan obtain ≥ 4 week follow initial documentation objective response progressive disease atezolizumab therapy . Atezolizumab give long patient continue experience clinical benefit opinion investigator unacceptable toxicity , symptomatic deterioration attribute disease progression . Patients follow 12 month death per standard care discontinuation Atezolizumab death , whichever occur first .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients Stage IIIB/IV squamous nonsquamous NSCLC ( American Joint Committee Cancer 7th Edition Staging ) prior treatment nivolumab pembrolizumab enrol one 3 parallel cohort base follow : Cohort 1 : Patient progressive disease nivolumab pembrolizumab best overall response . Progressive disease must confirm confirmatory scan ≤ 4 week 1st documented date progression . Cohort 2 : Patients stable disease best overall response minimum 12 week therapy nivolumab pembrolizumab . Cohort 3 : Patients partial complete response best overall response follow progressive disease , nivolumab pembrolizumab . A confirmatory scan time disease progression must perform ≤ 4 week 1st documented date progression . Both men woman race ethnic group eligible trial Patients must resolution toxic effect Grade 1 less prior therapy ( except alopecia ) . Patients must sign Informed Consent Form show ability willingness comply requirement study protocol . 18 year age old Willingness undergo biopsy ≤ 6 week start study treatment obtain formalinfixed paraffinembedded tumor specimen paraffin block ( block prefer ) least 15 unstained slide , associate pathology report , central test tumor PDL1 expression . Adequate hematologic end organ function , define follow laboratory result obtain within 14 day prior first study treatment ( Cycle 1 , Day 1 ) : ANC equal to/greater 1500 cells/µL WBC count great 2500/µL Lymphocyte count equal to/greater 300µ/L Platelet count equal to/greater 100,000/µL Hemoglobin equal to/greater 9.0 g/dL Total bilirubin equal to/less 1.5 x ULN follow exception : Patients know Gilbert disease serum bilirubin level equal to/less 3 x ULN may enrol . AST ALT equal to/less 3.0 x ULN follow exception : Patients liver involvement : AST and/or ALT equal to/less 5 x ULN Alkaline phosphatase equal to/less 2.5 x ULN follow exception : Patients document liver involvement bone metastasis : alkaline phosphatase equal to/less 5 x ULN Serum creatinine equal to/less 1.5 x ULN creatinine clearance equal to/greater 50 mL/min basis CockcroftGault glomerular filtration rate estimation . Measurable disease per RECIST v1.1 patient solid malignancy . For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use highly effective form ( ) contraception ( i.e. , one result low failure rate [ le 1 % per year ] use consistently correctly ) continue use 5 month last dose Atezolizumab . Eastern Cooperative Oncology Group Performance Status 0 1 . Patients ECOG Performance Status 2 allow discretion Treating Investigator agreement SponsorInvestigator . INR aPTT equal to/less 1.5 x ULN . This apply patient receive therapeutic anticoagulation ; patient receive therapeutic anticoagulation ( lowmolecularweight heparin warfarin ) stable dose . Any approved anticancer therapy , include chemotherapy , hormonal therapy , radiotherapy , within 3 week prior initiation study treatment ; however , follow allow : Hormonereplacement therapy oral contraceptive . Herbal therapy great 1 week prior Cycle 1 , Day 1 ( herbal therapy intend anticancer therapy must discontinue least 1 week prior Cycle 1 , Day 1 ) . Palliative radiotherapy bone metastases great 2 week prior Cycle 1 , Day 1 . Adverse event prior anticancer therapy resolve Grade equal to/less than1 except alopecia . History grade 4 immunerelated adverse event require treatment prednisone history grade 3 immunerelated adverse event require prednisone &gt; 10 mg/kg &gt; 12 week . Bisphosphonate therapy symptomatic hypercalcemia ( use bisphosphonate therapy reason ( e.g. , bone metastasis osteoporosis ) allow ) . Known clinically significant liver disease , include active viral , alcoholic , hepatitis ; cirrhosis ; fatty liver ; inherit liver disease . Patients acute leukemia , accelerated/blast phase chronic myelogenous leukemia , chronic lymphocytic leukemia , Burkitt lymphoma , plasma cell leukemia , nonsecretory myeloma . Known primary central nervous system ( CNS ) malignancy symptomatic CNS metastasis . Patients asymptomatic untreated CNS disease may enrol , provide follow criterion meet : Evaluable measurable disease outside CNS . No metastases brain stem , midbrain , pons , medulla , cerebellum , within 10 mm optic apparatus ( optic nerve chiasm ) . No history intracranial hemorrhage spinal cord hemorrhage . No ongoing requirement dexamethasone CNS disease ; patient stable dose anticonvulsant permit . No neurosurgical resection brain biopsy within 28 day prior Cycle 1 , Day 1 . Patients asymptomatic treat CNS metastasis may enrol , provide criterion list met well follow : Radiographic demonstration improvement upon completion CNS direct therapy evidence interim progression completion CNSdirected therapy screen radiographic study . No stereotactic radiation wholebrain radiation within 28 day prior Cycle 1 , Day 1 . Screening CNS radiographic study equal to/greater 4 week completion radiotherapy equal to/greater 2 week discontinuation corticosteroid . Patients pregnant , lactation , breastfeed . Known hypersensitivity Chinese hamster ovary cell product recombinant human antibody . Inability comply study followup procedure . History risk autoimmune disease , include limited systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , Bell 's palsy , GuillainBarré syndrome , multiple sclerosis , autoimmune thyroid disease , vasculitis , glomerulonephritis . Patients history autoimmune hypothyroidism stable dose thyroid replacement hormone may eligible . Patients control Type 1 diabetes mellitus stable insulin regimen may eligible . Patients eczema , psoriasis , lichen simplex chronicus vitiligo dermatologic manifestation ( e.g. , patient psoriatic arthritis would exclude ) permit provided meet following condition : Patients psoriasis must baseline ophthalmologic exam rule ocular manifestation . Rash must cover less 10 % body surface area ( BSA ) . Disease well control baseline require low potency topical steroid ( e.g. , hydrocortisone 2.5 % , hydrocortisone butyrate 0.1 % , fluocinolone 0.01 % , desonide 0.05 % , alclometasone dipropionate 0.05 % ) . No acute exacerbation underlie condition within last 12 month ( require psoralen plus ultraviolet A radiation [ PUVA ] , methotrexate , retinoids , biologic agent , oral calcineurin inhibitor ; high potency oral steroid ) . History idiopathic pulmonary fibrosis , pneumonitis ( include drug induce ) , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia , etc . ) , evidence active pneumonitis screen chest compute tomography ( CT ) scan . History radiation pneumonitis radiation field ( fibrosis ) permit . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication . History HIV infection active hepatitis B ( chronic acute ) hepatitis C infection . Patients past resolve hepatitis B infection ( define negative hepatitis B surface antigen [ HBsAg ] test positive antiHBc [ antibody hepatitis B core antigen ] antibody test ) eligible . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV RNA . Active tuberculosis . Severe infection within 4 week prior Cycle 1 , Day 1 , include limited hospitalization complication infection , bacteremia , severe pneumonia . Signs symptoms infection within 2 week prior Cycle 1 , Day 1 . Received oral IV antibiotic within 2 week prior Cycle 1 , Day 1 . Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection chronic obstructive pulmonary disease ) eligible . Major surgical procedure within 28 day prior Cycle 1 , Day 1 anticipation need major surgical procedure course study . Administration live , attenuated vaccine within 4 week enrollment anticipation live attenuated vaccine require study 5 month last dose Atezolizumab . Influenza vaccination give influenza season ( approximately October March ) . Patients must receive live , attenuate influenza vaccine ( e.g. , FluMist ) within 4 week prior enrollment , time study , 5 month last dose Atezolizumab . Malignancies disease study within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) undergo active surveillance per standardofcare management ( e.g. , chronic lymphocytic leukemia Rai Stage 0 , prostate cancer Gleason score equal to/less 6 , prostatespecific antigen equal to/less than10 mg/mL , etc. ) . Treatment investigational agent within 4 week prior Cycle 1 , Day 1 ( within five half live investigational product , whichever long ) . Treatment systemic immunosuppressive medication ( include limit prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) within 2 week prior Cycle 1 , Day 1 . Patients receive acute , low dose , systemic immunosuppressant medication ( e.g. , onetime dose dexamethasone nausea ) may enrol . The use inhale corticosteroid mineralocorticoid ( e.g. , fludrocortisone ) patient orthostatic hypotension adrenocortical insufficiency allow . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein . Patients prior allogeneic bone marrow transplantation prior solid organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>